BioAtla Results Presentation Deck

Sarcoma Phase 2 Part 1 Design: Predefined Interim Analysis Decision Tree PHASE 2 - SARCOMA STS Monotherapy Bone Combo with PD-1 LMS Syn Lipo Others Osteo Ewing Others ~10 patients w TmPS>=70 ~10 patients w TmPS>=70 ~10 patients w TmPS>=70 ~10 patients w TmPS>=70 ~10 patients w TmPS>=70 ~10 patients w TmPS>=70 ~10 patients w TmPS>=70 ~10 patients w CD20 pos ~10 patients w CD20 neg For each Subgroup up to 10 patients No Go if 0 CR/PR and PFR12 week < 40% Go if ≥ 1 CR/PR or PFR12 week ≥ 40% bicatla Mecbotamab vedotin - BA3011 3

View entire presentation